(Q36615874)

English

Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours

scientific article published on May 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours (English)

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

pharmacokinetics

1 reference

based on heuristic

inferred from title

author name string

Awada A

1

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Hendlisz A

2

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Gil T

3

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Bartholomeus S

4

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Mano M

5

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

de Valeriola D

6

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Strumberg D

7

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Brendel E

8

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Haase CG

9

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Schwartz B

10

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Piccart M

11

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

language of work or name

0 references

publication date

1 May 2005

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

British Journal of Cancer

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

92

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

10

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

1855-1861

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361774

30 September 2017

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361774

30 September 2017

Mutations of the BRAF gene in human cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361774

30 September 2017

Discovery of a novel Raf kinase inhibitor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361774

30 September 2017

Analysis of the transcriptional program induced by Raf in epithelial cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361774

30 September 2017

MEK kinase activity is not necessary for Raf-1 function

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361774

30 September 2017

Ras activation of the Raf kinase: tyrosine kinase recruitment of the MAP kinase cascade

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361774

30 September 2017

Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361774

30 September 2017

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361774

30 September 2017

B-Raf inhibits programmed cell death downstream of cytochrome c release from mitochondria by activating the MEK/Erk pathway

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361774

30 September 2017

Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361774

30 September 2017

Endothelial apoptosis in Braf-deficient mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361774

30 September 2017

Induction of cell proliferation in quiescent NIH 3T3 cells by oncogenic c-Raf-1.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361774

30 September 2017

Bcl-2 targets the protein kinase Raf-1 to mitochondria

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361774

30 September 2017

Both v-Ha-Ras and v-Raf Stimulate Expression of the Vascular Endothelial Growth Factor in NIH 3T3 Cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361774

28 June 2018

RAF/RAS oncogenes and mismatch-repair status

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6602584

21 January 2018

Independent control of cell survival by Raf-1 and Bcl-2 at the mitochondria

1 reference

https://pubmed.ncbi.nlm.nih.gov/15870716

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/SJ.BJC.6602584

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36615874&oldid=2199094883"